GlassScriptPhysician profile
Laura Weldishofer
NPI 1669861787
$1,754.47
in general payments reported to CMS, 2019-2025
28 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2022: $307 · 2023: $77.75 · 2024: $652 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.59 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $219.48 | 2021-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $170.99 | 2023-2025 | |
| Abbvie INC. | $158.82 | 2024-2025 | |
| Janssen Biotech, INC. | $143.40 | 2025 | Rybrevant, Carvykti, Talvey |
| Boston Scientific Corporation | $124.50 | 2021 | |
| Progenics Pharmaceuticals, INC. | $115.02 | 2022 | |
| Gilead Sciences, INC. | $114.29 | 2024-2025 | Trodelvy |
| Novocure INC. | $85.86 | 2022-2025 | Optune Lua (Novottf-200t) |
| Astrazeneca Pharmaceuticals LP | $84.15 | 2024-2025 | Imfinzi |
| Tersera Therapeutics LLC | $74.49 | 2024-2025 | Zoladex |
| Merck Sharp & Dohme LLC | $67.92 | 2024-2025 | Keytruda, Welireg |
| Pfizer INC. | $40.78 | 2024 | |
| Lilly USA, LLC | $34.32 | 2024 | Verzenio, Jaypirca, Retevmo |
| Beigene USA, INC. | $29.78 | 2024 | Brukinsa |
| Taiho Oncology, INC. | $26.28 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $24.60 | 2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $24.42 | 2024 | Fruzaqla |
| Tempus Ai, INC | $23.66 | 2024 | |
| Sun Pharmaceutical Industries INC. | $22.91 | 2024 | |
| Incyte Corporation | $22.75 | 2024 | Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $21.86 | 2025 | Enhertu |
| Celgene Corporation | $21.46 | 2024 | Reblozyl |
| Tactile Systems Technology INC | $20.00 | 2023 | |
| Recordati_rare_diseases_inc. | $19.80 | 2025 | Sylvant |
| Seagen INC. | $17.55 | 2023 | Tukysa |
| Amgen INC. | $16.09 | 2023 | Lumakras |
| Astellas Pharma US INC | $15.08 | 2025 | Padcev |
| Array Biopharma INC | $14.21 | 2024 | Mektovi, Lorbrena, Xalkori |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Weldishofer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.